Implementation of a hospital radiopharmacy in a molecular imaging center: challenges, opportunities, and perspectives
Abstract
The Uruguayan Centre for Molecular Imaging (CUDIM) is a national initiative to cover molecular imaging needs on oncologic, neurologic and cardiovascular diseases, being this technology not available before its creation. Besides the aforementioned purposes, its objectives are also research of new clinical protocols, and development of new PET tracers, as well as education and training on this specialized area. A center with clinical and preclinical areas enables to achieve goals related to patient services, research and development. To accomplish these objectives, equipment is required to perform radiopharmaceutical synthesis, characterization and quality control. Taking into account the patient safety and quality standards, radioprotection and pharmaceutical issues must be fulfilled. 68Ga-DOTA-TATE, 18F-2-fluoro-2-deoxyglucose and, 11C-methionine are produced on regular basis; 11C-choline, 18F-fluoride y 68Ga-gallgas have been added recently. PET studies are supported by the “Fondo Nacional de Recursos” (FNR) to all the Uruguayan population. Radiopharmaceutical indications have been protocoled for oncology and neurology diseases. The design, implementation, start and development of a Radiopharmacy with clinical, research and development purposes need a multidisciplinary staff with a background on Pharmaceutical sciences and training on Radiochemistry/Radiopharmacy. CUDIM is an initiative to promote the molecular imaging development at national and regional level, having gathered all the efforts of those who feel identified with these goals.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2012 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.